Boule Diagnostics AB OMXSTO:BOUL:
BOULE DIAGNOSTICS ANNOUNCES CEO TRANSITION AS ORGANIZATION PREPARES FOR NEXT CHAPTER
TORBEN NIELSEN, CHIEF EXECUTIVE OFFICER, HAS DECIDED TO LEAVE COMPANY
Boule Diagnostics CEO Torben Nielsen To Leave Company
Watch Boule Diagnostics' latest callBoule Diagnostics (Stockholm:BOUL) Q3 2026 Earnings Call · Replay · Oct 23Read the transcript of Boule Diagnostics (Stockholm:BOUL) Q3 2026 Earnings CallEarlier from Boule Diagnostics
- BOUL: Organic growth and strong instrument sales drive improved cash flow amid margin pressure
- Boule Diagnostics CFO Leaves Company
- BOUL: Instrument sales surged 17% but lower prices and costs led to margin decline; cash flow turned positive
- BOUL: Sales fell 25% YoY, but margins improved and OEM growth offset hematology weakness
- BOUL: Margins improved and cost savings realized, with OEM growth and new U.S. distribution boosting outlook
Later from Boule Diagnostics
- Boule Diagnostics Selected As Provider In Tender In Italy
- Boule Diagnostics Appoints Michael Af Winklerfelt As CFO
- Boule Diagnostics Renews, Expands Global Supply Agreement
- Boule Diagnostics – Invitation to presentation of the Q4 report 2025
- BOUL: Revenue fell 12% amid restructuring, but operational improvements and portfolio expansion drive future growth
Follow Boule Diagnostics into a list and get an email when it puts out news.
Follow Boule Diagnostics